Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
FATE•Q2 results
- US biopharmaceutical firm's Q2 collaboration revenue rose modestly yr/yr
- Net loss for Q2 narrowed compared to prior yr, driven by lower operating expenses
| Metric | Actual |
|---|---|
| Q2 Collaboration Revenue | $2.08 mln |
| Q2 Net Loss | $30.16 mln |
| Q2 Income from Operations | -$31.13 mln |
| Q2 Loss Per Basic Share | $0.25 |
| Q2 Operating Expenses | $33.22 mln |
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.50, about 139% above its August 12 closing price of $2.72
Outlook and clinical updates
-
Company aims to complete RECLAIM-LN trial enrollment in first half of 2028
-
Fate expects to provide FT839 enrollment update later in 2026
-
Company expects FT836 clinical update in first half of 2027
